Alexza’s Revised Adasuve REMS Borrows From Risk Management Plan For Zyprexa Relprevv
This article was originally published in The Pink Sheet Daily
Executive Summary
A resubmitted Risk Evaluation and Mitigation Strategy that proposes to limit use of inhaled loxapine to health care facilities with ready access to advanced airway support borrows from language in the REMS for Lilly’s long-acting intramuscular injection formulation of olanzapine, Alexza’s CEO says.